{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"11.4","value":"8.6"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"2.5","upperLimit":"NA","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"At baseline and at end of treatment 40-day follow-up visit","title":"Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores","type":"SECONDARY","unitOfMeasure":"months"}